Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

POM Decision Will Free FTC Resources For Other Enforcement

This article was originally published in The Tan Sheet

Executive Summary

With the POM Wonderful litigation off its desk, FTC will have more resources to bring cases against other advertisers, attorney Mark Ullman warns. Likely target areas in 2013 and beyond include social media marketing and more subtle disease claims.

You may also be interested in...



Top 10 Trends In Food, Supplement Labeling Litigation

Lawyers who took down big tobacco have food and supplement advertising in their crosshairs, industry lawyer Prochnow says. He warns that among the top 10 enforcement trends are cases for unsubstantiated claims, “all natural” claims, dangerous failure to warn, nutrient content claims and “healthy” claims.

Top 10 Trends In Food, Supplement Labeling Litigation

Lawyers who took down big tobacco have food and supplement advertising in their crosshairs, industry lawyer Prochnow says. He warns that among the top 10 enforcement trends are cases for unsubstantiated claims, “all natural” claims, dangerous failure to warn, nutrient content claims and “healthy” claims.

FTC’s Stern POM Opinion Expands Disease Claim Findings

The Federal Trade Commission’s 5-0 decision against POM Wonderful finds the firm made false and misleading claims and requires it to conduct at least two randomized controlled clinical trials for all future disease-related claims. POM vows to appeal the order in federal court.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS106177

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel